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Lay summary
Currently available laboratory systems
are unable to reproduce the dynamics of
hepatitis B virus (HBV) spread through
the infected liver and release into the
blood. We developed a slowly dividing
liver-derived cell line which multiplies
infectious viral particles upon inoculation
with patient- or cell culture-derived HBV.
This new infection model can improve
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specific antiviral drugs.Viral Hepatitis. This is an open access article under the CC BY-NC-ND
9–300
o
i
u
o
Park , Sang Hoon Ahn , Kwang-Hyub Han ,
, Marc Peter Windisch1,2,⇑
na
,
SA
S
e
-
JOURNAL 
OF HEPATOLOGY
Research Article
Viral HepatitisEfficient long-term amplificati
after infection of slow prol
Alexander König1,y, Jaewon Yang1,y, Eunji Jo1, Ky
Xiyong Song3, Xiaoxuan Qi3, Xinghong Dai3, S
Jung-Hee Kim6, Seung Kew Yoon6, Jun Yong
Wolfram Hubert Gerlich8
1Applied Molecular Virology Laboratory, Institut Pasteur Korea, Seong
University of Science and Technology, 217, Gajeong-ro, Yuseong-gu
School of Medicine, Case Western Reserve University, Cleveland, OH, U
South Korea; 5Department of Biochemistry, Yonsei University, Seoul,
University of Korea, Seoul, South Korea; 7Department of Internal M
8Institute of Medical Virology, Justus
Background & Aims: As hepatitis B virus (HBV) spreads
through the infected liver it is simultaneously secreted into
the blood. HBV-susceptible in vitro infection models do not efﬁ-
ciently amplify viral progeny or support cell-to-cell spread. We
sought to establish a cell culture system for the ampliﬁcation of
infectious HBV from clinical specimens.
Methods: An HBV-susceptible sodium-taurocholate cotrans-
porting polypeptide-overexpressing HepG2 cell clone (HepG2-
NTCPsec+) producing high titers of infectious progeny was
selected. Secreted HBV progeny were characterized by native
gel electrophoresis and electron microscopy. Comparative
RNA-seq transcriptomics was performed to quantify the expres-
sion of host proviral and restriction factors. Viral spread routes
were evaluated using HBV entry- or replication inhibitors, visu-
alization of viral cell-to-cell spread in reporter cells, and nearest
neighbor infection determination. Ampliﬁcation kinetics of HBV
genotypes B-D were analyzed.
Results: Infected HepG2-NTCPsec+ secreted high levels of large
HBV surface protein-enveloped infectious HBV progeny with
typical appearance under electron microscopy. RNA-seq tran-
scriptomics revealed that HBV does not induce signiﬁcant gene
expression changes in HepG2-NTCPsec+, however, transcription
factors favoring HBV ampliﬁcation were more strongly
expressed than in less permissive HepG2-NTCPsec. Upon inoc-
ulation with HBV-containing patient sera, rates of infected cells
increased from 10% initially to 70% by viral spread to adjacent
cells, and viral progeny and antigens were efﬁciently secreted.
HepG2-NTCPsec+ supported up to 1,300-fold net ampliﬁcation
of HBV genomes depending on the source of virus. Viral spreadKeywords: Complete HBV life cycle; HepG2-NTCP; Patient-derived HBV; Drug
sensitivity; Kinetics of antigen; Virion secretion; cccDNA accumulation; HBV
doubling time; HBV spread.
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and ampliﬁcation were abolished by entry and replication inhi-
bitors; viral rebound was observed after inhibitor
discontinuation.
Conclusions: The novel HepG2-NTCPsec+ cells efﬁciently sup-
port the complete HBV life cycle, long-term viral spread and
ampliﬁcation of HBV derived from patients or cell culture,
resembling relevant features of HBV-infected patients.
Lay summary: Currently available laboratory systems are
unable to reproduce the dynamics of hepatitis B virus (HBV)
spread through the infected liver and release into the blood.
We developed a slowly dividing liver-derived cell line which
multiplies infectious viral particles upon inoculation with
patient- or cell culture-derived HBV. This new infection model
can improve therapy by measuring, in advance, the sensitivity
of a patient’s HBV strain to speciﬁc antiviral drugs.
 2019 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Despite vaccination, chronic hepatitis B (CHB) has remained
among the most widespread, life-shortening infectious diseases.
Two billion people worldwide have been infected with the hep-
atitis B virus (HBV), including 257 million chronic carriers. Up to
30% of chronically HBV-infected adults will develop liver cirrho-
sis or hepatocellular carcinoma, accounting for 887,000 deaths
annually.1 Reverse transcriptase inhibitors and interferon-
alpha can control viral replication and prevent CHB progression.
However, these therapies do not act on HBV genomes in host
cell nuclei that persist as covalently closed circular DNA
(cccDNA). Thus, current treatment regimens are not curative,
requiring lifelong therapy.
HBV has a restricted host range and a narrow tissue tropism
which has hampered the study of the HBV life cycle and the dis-
covery of new therapeutic approaches. Only highly differenti-
ated hepatocyte-derived cells from human or tree shrew
(Tupaia) can be used for in vitro HBV infection studies. Hepato-
cytes derived from common laboratory animals like mice, rats,019 vol. 71 j 289–300
dogs, macaques or pigs do not support HBV infection.2,3 The cur-
rent gold standard for in vitro infection studies utilizes primary
human hepatocytes (PHHs) and patient-derived HBV. However,
PHH drawbacks include high cost, limited availability, difﬁcult
handling, donor variability, and dedifferentiation leading to
rapid loss of HBV susceptibility and replication.4 The hepatoma
HepaRG cell line requires laborious re-differentiation that
results in only moderate HBV susceptibility.5 Novel models,
i.e. self-assembling co-cultures (SACC) of PHHs with non-
parenchymal liver cells, as well as a 3D microﬂuidic PHH sys-
tem, can support persistent infection with cell culture and puri-
ﬁed patient-derived HBV strains for 5-6 weeks, but no
ampliﬁcation and spread of HBV has been observed to date,
and both models depend on human liver tissue.6,7 Other
promising systems are human hepatocyte-like cells (HLC) gen-
erated from induced pluripotent stem cells or embryonic stem
cells which are susceptible to HBV and support limited viral
production and spread.8,9
A major breakthrough was the discovery of the sodium-
taurocholate cotransporting polypeptide (NTCP) as the
differentiation-dependent, hepatocyte- and species-speciﬁc cell
membrane HBV receptor.10 Although hepatoma cell lines, such
as HepG2 and Huh-7, replicate HBV after transfection with
HBV DNA, they are not susceptible to HBV infection. However,
they can be rendered susceptible by NTCP overexpression. Efﬁ-
cient infection of these and other cells requires treatment with
polyethylene glycol (PEG) during HBV attachment and/or entry
to enhance glycosaminoglycan-dependent binding.11 Dimethyl-
sulfoxide (DMSO) is used to slow down cell proliferation, extend
lifespan, increase differentiation status, and enhance suscepti-
bility and HBV replication. However, following HBV infection
and episomal cccDNA formation, these cells fail to amplify the
viral genomes, hampering viral progeny production, and spread
in cell culture.
HBV-transfected hepatoma cells, including HepAD38 and
HepG2.2.15, have been used to produce cell culture-derived
HBV (HBVcc) and to investigate late stages of the viral life cycle.
Less laborious and expensive in vitro infection systems with an
Naïve HepG2-NTCPsec+ p2-cells were seeded in infection med-
ium into 384-well plates 24 h before inoculation. For p2-cell
infection, supernatants of HBVcc-infected p1-cells were trans-
ferred to p2-cells at 6 days post-infection (dpi) in the presence
of 4% PEG. After 24 h, cells were washed and incubated with
fresh medium for 120 h.
For further details regarding the materials and methods
used, please refer to the CTAT table and supplementary
information.
Results
Infectious HBV progeny production in slowly proliferating
HepG2-NTCP cells
Our goal was to identify an HBV-susceptible HepG2-NTCP clone
with enhanced production of infectious HBV progeny. We sub-
jected a previously described HepG2-NTCP cell clone (parental
clone) to reselection for NTCP overexpression by increasing
the blasticidin selection pressure (15 lg/ml) for 6 weeks.13 Five
new HepG2-NTCP clones were selected and HBV susceptibility
tested (Fig. 1A). The parental cell clone and another published
HepG2-NTCP reference clone (sec), were used as controls.14
Beside clone #3, all clones showed detectable NTCP expression
and similar levels of myrcludex B (MyrB)-sensitive HBV suscep-
tibility (Fig. 1B). To test the production of infectious HBV pro-
geny by the different clones, we infected p1 cells with serially
diluted HBV and passaged the supernatants to naïve p2 cells
for infection (Fig. 1C). Depending on the inoculum size, p1 infec-
tion rates varied between 10–90% (Fig. 1D, upper panel). Clone
#5 was superior in the secretion of infectious viral progeny and
was therefore named HepG2-NTCPsec+ (Fig. 1D, lower panel).
Only viral progeny secreted from the HepG2-NTCPsec+ infected
up to 50% of p2 cells while all other clones showed lower abil-
ities in HBV secretion. Lamivudine (LMV), an HBV replication
inhibitor, abrogated the infectivity of the p1 supernatant for
p2 cells, demonstrating that the p2 cell infection was caused
by secreted progeny virions and not by carryover of input virus
(Fig. 1E).
Research Article Viral Hepatitisunlimited supply that support the complete HBV life cycle and
more closely resemble hepatocytes in the human liver, by
allowing for more efﬁcient ampliﬁcation and spread of viral
progeny, would be highly desirable (reviewed in 12). In this
study, we identify and characterize a slowly proliferating
HepG2-NTCP clone that supports the efﬁcient secretion of
highly infectious HBV progeny upon infection with patient-
and cell culture-derived virus, and elucidate the kinetics and
routes of viral ampliﬁcation during long-term infection.
Materials and methods
HBV infection and progeny passaging
First HBV passage (p1): HepG2-NTCPsec+ were incubated in
384-well plates (8,000 cells/well) for 18 h in infection medium.
p1-cells were inoculated at 37 C for 24 h with HepAD38-
cell-harvested HBVcc genotype D (2,500 genome equivalents
[GEq]/cell, 5  108 GEq/ml) or with diluted crude sera from 7
Korean patients with CHB, unless otherwise indicated, with 4%
PEG8000. For inhibition of HBV infection, cells were treated
with inhibitors 2 h before and during inoculation. Following
inoculum removal and washing, cells were incubated for
120 h in infection medium with or without reference inhibitors.290 Journal of Hepatology 2Notably, the NTCP expression level in HepG2-NTCPsec is 2-
fold higher than in sec+ as determined by quantiﬁcation of
immunoﬂuorescence images, leading to increased taurocholic
acid uptake and binding capacity for HBV as shown by a 2–
10-fold elevated plasma membrane accumulation of myr-
preS1-Alexa633 peptide in live-cell imaging and FACS analysis
(Fig. S1A-D). Comparing cell doubling times (t2) identiﬁed
HepG2-NTCPsec+ with a 2-fold reduced growth rate
(t2 = 13.1 days) relative to that of HepG2-NTCPsec with a typ-
ical t2 of 6.7 days (Fig. S2A). Slow-growing HepG2-NTCPsec+
were larger and less numerous upon cell conﬂuency (Fig. S2B),
with a signiﬁcantly larger fraction of cells within the non-
dividing G0/G1 cell cycle phase (Fig. S2C). DMSO extended the
HepG2-NTCPsec+ lifespan, enabling long-term culture for up
to 8 weeks without a signiﬁcant decrease in cell numbers and
metabolic activity as shown by robust ATP levels (Fig. S2D). To
test whether HBV progeny production in HepG2-NTCP cells
depends on the cell cycle, we knocked down CDK6, which
regulates the G1/S phase progression (Fig. S2E). After conﬁrming
a 70% reduction of CDK6mRNA level, HepG2-NTCP cells showed
markedly decreased proliferation, a minor increase in the
number of de novo infected cells, and signiﬁcantly increased
production of infectious HBV progeny (Fig. S2F).019 vol. 71 j 289–300
Characterization of HepG2-NTCPsec+ derived HBV progeny
Next, we compared the secretion of HBV over 4 weeks after
inoculation of HepG2-NTCPsec and sec+ with a high-dose of
HBVcc (5,000 GEq/cell or 8  108 GEq/ml). As a marker of infec-
tion, HBV core antigen (HBcAg) was expressed robustly for
4 weeks in > 90% of cells in both clones (Fig. 2A). However, at
4 weeks post infection (wpi), HepG2-NTCPsec secreted 3-fold
lower HBV e antigen (HBeAg) and 16-fold less HBV surface
antigen (HBsAg) (Fig. 2B). Also, HBV DNA levels secreted by
HepG2-NTCPsec did not reach the DNA input level whereas
HepG2-NTCPsec+ secreted higher numbers of HBV DNA, which
demonstrated net ampliﬁcation of viral genomes (Fig. 2B). We
compared secretion of HBV genomes in PHH at 11 and 15 dpi,
before the signal vanished at 20 dpi (Fig. S3A). Compared to
HBcAg capsids (Fig. 2C). In contrast, HepG2-NTCPsec+ secreted
increasing high levels of enveloped viral particles (Fig. 2C).
Accordingly, infectivity of the supernatants increased over time
(Fig. S4). HBV-transfected producer cells HepAD38 secreted 10-
fold more non-infectious ‘‘naked” capsids than LHBs-enveloped
virions (Fig. 2C). Accordingly, HepG2-NTCPsec+ inocula were
more infectious than those of HepAD38 cells (Fig. 2E). In contrast
to HBV-infected HepG2-NTCPsec and transfected HepAD38
cells, HepG2-NTCPsec+ secreted >100-fold more LHBs-
enveloped HBV particles and no detectable naked capsids.
Similarly, the serum from a highly contagious patient with
CHB contained high levels of enveloped HBV capsids and no
naked capsids (Fig. 2D). The serum also contained slowly
migrating and faster-migrating LHBs containing particles
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Fig. 1. Selection of a HepG2-NTCP clone capable of secreting infectious progeny HBV. (A) Workﬂow for HBV infection. Seven different HepG2-NTCP clones
were cultured with or w/o MyrB, followed by infection with HBVcc. (B) NTCP-speciﬁc immunoﬂuorescence analysis (green, upper panel), HBcAg-speciﬁc
immunoﬂuorescence analysis (green) of HBV-infected cells w/o (middle panel) or with MyrB treatment (lower panel). Cell nuclei (blue). (C) Workﬂow of HBV
infection and supernatant transfer. Cells (p1) were infected with serially diluted HBVcc and cultured +/- LMV, followed by supernatant transfer to p2 cells. (D)
Image quantiﬁcation of HBV-infected p1 and p2 HepG2-NTCP cells. (E) HBcAg-speciﬁc immunoﬂuorescence analysis of p1 and p2 HepG2-NTCPsec and mock-
or 10 lM LMV-treated HepG2-NTCPsec+. Mean HBV infection rates (%) are indicated in each image. Data presented as means ± SD of triplicate wells with 6
images/well (n = 18). Student’s t test (*p <0.05, **p <0.01, ***p <0.001, n.s. not signiﬁcant). HBc, HBV core antigen; HBV, hepatitis B virus; LMV, lamivudine;
MyrB, myrcludex B; p1, passage 1; p2, passage 2.
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OF HEPATOLOGYHepG2-NTCPsec+, we determined a similar daily secretion rate
of HBV genomes and HBeAg, but a 4-fold lower production of
small HBV surface protein (SHBs) per infected cell by PHH
(Fig. S3B). Similar to HepG2-NTCPsec, parental HepG2-NTCP
cells and other clones showed lower secretion levels of all viral
markers (Fig. S3C).
The structure of secreted HBV-related particles was analyzed
by native western blotting using anti-HBc or anti-preS1 antibod-
ies, which recognize the large HBV surface antigen (LHBsAg).
HepG2-NTCPsec produced low levels of LHBs-envelopedJournal of Hepatology 2without capsids which were absent in the sec+ samples.
However, Dane particles of 45 nm in diameter, as well as
23 nm spherical and ﬁlamentous subviral particles of heteroge-
neous length were produced by infected HepG2-NTCPsec+ as
visualized by negative-staining electron microscopy (Fig. 2F).
Comparative transcriptomics of HepG2-NTCPsec+ and
HepG2-NTCPsec
In search for cellular factors which could explain the marked
differences in HBV progeny secretion between HepG2-NTCPsec019 vol. 71 j 289–300 291
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Research Article Viral Hepatitis+ and sec, we conducted a comparative transcriptomic analy-
sis in the presence and absence of HBV (Fig. 3A). Strikingly,
using stringent parameters of p value <0.01 and q-value <0.05
for the analysis of triplicates, no gene transcripts were
uniformly induced or repressed by HBV infection of HepG2-
NTCPsec+ compared to naïve sec+, just as shown for chim-
panzees during the lag phase of HBV infection (weeks 0–2) or
the phase of logarithmic expansion (weeks 4–6) (Fig. 3A, left).15
However, in HepG2-NTCPsec that fail to produce infectious
progeny virions, 1,364 genes were changed due to HBV infection
Naked
capsids
3x106 6x106 7x106 4x106 1x107 4x107 6x107 7x107HBV genomes: 5x10
Fig. 2. Infectivity of HepG2-NTCPsec+-released HBV progeny correlates wit
with HepAD38-derived HBV. (A) HBcAg-speciﬁc immunoﬂuorescence analysis
Levels of HBeAg (left), HBsAg (middle) and HBV genomes (right) secreted by H
horizontal line). Supernatants of 20 wells (384-well plate) were pooled and
enveloped capsids (virions) and non-enveloped naked capsids were analyzed b
indicated. (D) HBV particle pattern in serum of a patient with CHB. (E) Percent
+-derived HBV. (F) Negative-staining electron microscopy of HBV particles pr
signiﬁcant). HBcAg, HBV core antigen; HBeAg, HBV e antigen; HBV, hepatitis
surface antigen.LHB.292 Journal of Hepatology 2(689 upregulated, 675 downregulated) (Fig. 3A, right). Compar-
ing the total transcriptome comprising 18,149 genes, 5,494
genes were signiﬁcantly differentially expressed between
HBV-infected HepG2-NTCPsec+ and sec (2,755 upregulated
and 2,793 downregulated in sec+) (Fig. 3B) including host fac-
tors related to HBV entry, transcription, assembly and release.
As already demonstrated at the protein level (Fig. S1), NTCP
(SLC10A1) RNA levels were 2-fold higher in HepG2-
NTCPsec (Fig. 3C). Furthermore, most genes related to HBV
attachment, e.g. heparan sulfate proteoglycan (HSPG), AGRN,
Naked
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80 nm 2
3
48.2 nm2 23.5 nm4
HBsAg envelopment of nucleocapsids. HepG2-NTCPsec/sec+ were infected
nd nucleus staining of HBV-infected HepG2-NTCPsec/sec+ from 1-4 wpi. (B)
-infected HepG2-NTCPsec/sec+ were analyzed by ELISA or qPCR (input HBV,
analyzed as duplicates. (C) LHBs of enveloped HBV particles and HBcAg of
native western blotting. HBV genome numbers per 10 ll of supernatants are
fected HepG2-NTCPsec+ (7 dpi) inoculated with HepAD38- or HepG2-NTCPsec
duced by infected HepG2-NTCPsec+. (*p <0.05, **p <0.01, ***p <0.001, n.s. not
virus; LHBs, large HBV surface protein; qPCR, quantitative PCR; HBsAg, HBV019 vol. 71 j 289–300
glypicans (GPC) and syndecan 4 (SDC) were more highly
expressed in HepG2-NTCPsec (Fig. 3C). Among 11 previously
described HBV transcription factors, CEBPA, FXR, PPARA,
PPARGC1A/B and PPARG were 2- to 100-fold upregulated while
GEq/cell resulted in an initial infection rate of 30% at 1 wpi,
followed by a steady increase, plateauing at 80% by 4–5 wpi
(Fig. 4B). LMV suppressed this increase, indicating the spread
of newly produced viral progeny and ruling out delayed de novo
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Fig. 3. Comparative transcriptomic analysis of HepG2-NTCPsec+ and sec in the presence or absence of HBV. Total RNA was isolated at 2 weeks from naïve
or HBV-infected HepG2-NTCPsec+/sec. A cDNA library was generated and sequenced for mRNA comprising a total of 18,149 genes. (A) Scatter plots of
differentially expressed genes in HepG2-NTCPsec+ w/o HBV vs. sec+ with HBV (left) or HepG2-NTCPsecw/o HBV vs. secwith HBV (right). (B) Scatter plots of
differentially expressed genes in HepG2-NTCPsec+ with HBV vs. HepG2-NTCPsecwith HBV. (C-D) Log2-fold change in gene expression related to HBV entry (C)
or transcription (D) in HepG2-NTCPsec+ with HBV vs. HepG2-NTCPsec with HBV. Statistical signiﬁcance was determined for the analysis of triplicates (s,
p <0.01 and q <0.05; n.s., not signiﬁcant). HBV, hepatitis B virus.
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OF HEPATOLOGYonly HNF1Bwas 5-fold downregulated in sec+ compared to sec
using stringent parameters of p value <0.01 and q-value <0.05
for the analysis of triplicates (Fig. 3D). Furthermore, DDX3X
and DDX3Y, 2 cellular RNA helicases with known inhibitory
effects on HBV replication, were 6- and 2-fold higher expressed
in HepG2-NTCPsec, respectively (Fig. S5). However, HBV
restriction host factor APOBEC3G was 4-fold higher expressed
in sec+. Genes related to the preS1-dependent virion envelop-
ment as well as ESCRT0 complex were mainly upregulated in
sec+, while the ESCRT I, II, III secretory complexes which are
hijacked by HBV for egress, show a more heterogeneous expres-
sion pattern (Fig. S5).
Secretion of infectious progeny drives spread, re-infection,
cccDNA replenishment, and HBV amplification in HepG2-
NTCPsec+
Considering the high susceptibility and efﬁcient infectious pro-
geny secretion from HepG2-NTCPsec+, we followed HBV spread
in long-term (6-week) cultures (Fig. 4A). Inoculation with 500Journal of Hepatology 2infection by residual input HBV. Viral spread was abrogated by
neutralizing anti-HBs antibodies, indicating that HBV spreads
via the release of enveloped viral progeny into the extracellular
space. Moreover, HBV spread was also efﬁciently inhibited in
the presence of heparin, MyrB, or anti-preS1 antibodies in a
dose-dependent manner (Fig. 4C), indicating that like HBV entry
during inoculation with exogenous virus, the HBV S- and preS1
domain as well as cellular HSPG and NTCP are crucial entry fac-
tors for spread.
HBV spread correlated with accumulation of intracellular
cccDNA (Fig. 4D). As cccDNA is the template for pregenomic
RNA (pgRNA) which is converted into the relaxed circular
DNA (rcDNA) present in mature nucleocapsids and infectious
HBV, intracellular rcDNA synthesis also increased over time
(Fig. 4D). New cccDNA is, in turn, generated from rcDNA reim-
ported into the nucleus via recycling of de novo synthesized
cytoplasmic nucleocapsids or via receptor-mediated entry of
released virions. LMV, which blocks reverse transcription of
pgRNA into rcDNA, prevented cccDNA replenishment via both019 vol. 71 j 289–300 293
pathways (Fig. 4D). Anti-HBs treatment reduced, rather than
abrogated, rcDNA synthesis by preventing viral spread. How-
ever, in quantitative PCR (qPCR) we conﬁrmed that entry inhibi-
cccDNA molecules obtained from qPCR (Fig. 4E), we calculated
that the number of cccDNA molecules per infected cell was
increasing constantly from 1–8 within 6 weeks. In line with
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Fig. 4. The cccDNA pool in HepG2-NTCPsec+ cells is predominantly replenished via an extracellular route of spread and re-infection. (A) HepG2-NTCPsec+
were infected with HBVcc. The cells were subjected to mock, LMV, or anti-HBs, anti-LHBs, heparan, MyrB treatments for 6 weeks. (B) HBV-infected cells were
visualized by immunoﬂuorescence analysis of HBcAg. (C) Dose-dependent inhibition of HBV spread by entry inhibitors anti-SHBs, anti-preS1 LHBs directed
antibodies (MA18/07), MyrB and heparan. (D) Southern blot of HBV cccDNA and rcDNA, and semiquantitative analysis of respective bands. (E) Quantiﬁcation of
cccDNA by qPCR. (F) Quantiﬁcation of secreted rcDNA genomes by qPCR. Data presented as means ± SD of duplicate or triplicate wells. (*p <0.05, **p <0.01,
***p <0.001, n.s. not signiﬁcant). cccDNA, covalently closed circular DNA; HBV, hepatitis B virus; HBVcc, cell culture derived HBV; LHBs, large HBV surface
protein; LMV, lamivudine; MyrB, myrcludex B; qPCR, quantitative PCR; SHBs, small HBV surface protein.
Research Article Viral Hepatitistors suppressed cccDNA formation, suggesting that new cccDNA
is predominantly derived from de novo infection, rather than
from recycling of intracellular nucleocapsids (Fig. 4E). We esti-
mated that entry-dependent, extracellular routes account for
88% of HBV genome ampliﬁcation, with intracellular pathways
accounting for no more than 12% of cccDNA replenishment.
Secretion of viral genomes similarly increased over time, a trend
blocked by anti-HBs and LMV (Fig. 4F). Total rebound of HBV
progeny secretion occurred 1–2 weeks after LMV withdrawal
(Fig. S4).
At later time points, when de novo infection by spread to
naïve cells became undetectable, cccDNA and secreted viral
genomes continued accumulating, which was prevented by
entry and replication inhibitors. Using values of total cell num-
ber, the percentage of infected cells and the total number of294 Journal of Hepatology 2this, inoculation of sec+ with a high virus load and maintaining
the cells with a constantly high infection rate of 80–90% over
8 weeks (Fig. S6A) showed a weekly increase of secreted HBV
DNA, HBsAg and HBeAg levels over the entire assay period
(Fig. S6B). The increase was blocked by replication or entry inhi-
bitors when added to the cells at 2 dpi, indicating that re-
infection of already infected cells substantially contributes to
HBV ampliﬁcation. Long-term treatment with the inhibitors
had no signiﬁcant impact on cell viability (Fig. S6C).
HBV progeny spreads preferably to adjacent cells
The spatio-temporal pattern of HBV spread in infected cell cul-
tures (Fig. 5A) was followed by whole-well imaging of HBcAg-
positive cells using dedicated image mining software
(Fig. S7A). Evaluation of distance between infected cells019 vol. 71 j 289–300
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OF HEPATOLOGYrevealed the formation of HBV-positive cell clusters (Fig. S7B).
The HBV-infected clusters expanded over time, while entry inhi-
bitors MyrB and anti-HBs prevented the formation of larger
clusters (Fig. 5B). Mock-treated infected single cells rapidly
expanded to >50% of infected cells within clusters of >10
infected cells/cluster at 4 wpi, whereas inhibitor treatment sig-
niﬁcantly reduced the formation of larger cluster sizes (Fig. 5C).
To further visualize HBV spread on a single-cell level,
infected HepG2-NTCPsec+ were co-cultured for 1 week with
naïve HepG2-NTCPsec+ expressing the red ﬂuorescent protein
(Fig. 5D). Infected reporter cells were predominantly observed
adjacent to de novo HBV-infected cells, indicating that virus
transmission followed a cell-to-cell route (Fig. 5E). MyrB and
LMV reduced HBV spread to reporter cells by 6-fold
(Fig. 5F-G).
L
Fig. 5. HBV spreads to adjacent HepG2-NTCPsec+ cells. (A) Full-well images
cell distance analysis grouped HBV-infected cells into clusters highlighted u
quantiﬁcation of infected cells belonging to different cluster sizes at 1 and 4 wp
(E-F) Representative high magniﬁcation images of HBVcc-infected HepG2-NTC
arrowheads), and uninfected RFP reporter cells (red, stealth-shaped arrowhead
Quantiﬁcation of HBV-infected reporter cells. Mean and SD values were calcula
**p <0.01, ***p <0.001, n.s. not signiﬁcant). HBs, HBV surface protein; HBV,
myrcludex B; RFP, red ﬂuorescent protein; wpi, weeks post infection.Journal of Hepatology 2HBV in sera of patients with CHB persistently amplifies and
spreads in HepG2-NTCPsec+
As HepG2-NTCPsec+ supported propagation of HBVcc, we fur-
ther tested whether these cells support the propagation of
patient-derived HBV (HBVpt). We inoculated sec+ with 0.1–
20 ll of crude patient sera from 7 Korean patients with CHB
and differences in viral load and HBeAg status (Fig. 6A). As
determined by immunoﬂuorescence of HBc expression (Fig. 6B),
at 1 wpi, 4 out of 7 sera were found to be clearly infectious with
>2 the cut-off of 1% infected cells and infection rates propor-
tional to the inoculum concentration in GEq/cell (Fig. 6C).
Serum from patient #1 and #2, bearing the highest viral loads,
resulted in 47% and 56% infected cells within 1 week, respec-
tively, when inoculated with 5 ll serum, equivalent to 3,400
and 900 GEq/cell (Fig. 6C). Sporadic, single infected cells were
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detected using a minimum of 2 GEq/cell of HBVpt #6. The neg-
ative results for patients #4 and #5, the positive result of patient
#6 and the endpoint dilution enables the deﬁnition of a mini-
HBVpt genotype C infected cells and replicated as efﬁciently
as HBVcc with genotype D or B. On average, for genotypes D,
C and B, 7  107, 3.6  105 and 6.5  106 HBV genomes per ng
Source Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Genotype C1 C C C C1 C C
Serum
GEq/ml 5.45E + 09 1.45E + 09 4.07E + 08 1.05E + 07 1.83E + 06 2.14E + 07 3.46E + 08
HBs ng/ml 1.30E + 05 2.30E + 05 1.53E + 04 3.27E + 03 3.94E + 03 5.02E + 03 4.13E + 04
Ratio GEq/HBs 4.19E + 04 6.30E + 03 2.66E + 04 3.21E + 03 4.64E + 02 4.26E + 03 8.38E + 03
HBe + + + - + - -
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Fig. 6. Susceptibility of HepG2-NTCPsec+ to HBV genotype C clinical samples. (A) Sequencing conﬁrmed genotype, viral genome and HBsAg load, ratio of
viral genomes per ng HBs and HBeAg status of 7 patient sera. (B) Cells were inoculated with serial dilutions of crude sera from 7 patients with CHB.
Representatively, patient #1 infection visualized at 7 dpi by immunoﬂuorescence analysis of HBcAg and HBsAg. (C) HBcAg-positive cells were quantiﬁed for
infections with 7 patient sera at 1 wpi. Data presented as means ± SD of triplicate wells with 6 images/well (n = 18). CHB, chronic HBV infection; dpi, days post
infection; HBcAg, HBV core antigen; HBeAg, HBV e antigen; HBsAg, HBV surface antigen; HBV, hepatitis B virus; wpi, weeks post infection.
Research Article Viral Hepatitismum infectious dose, suggesting that the detection limit for
infectious virions in serum at 1 wpi is 2  107 to 3  108 GEq/
ml. However, serum of patient #7 caused no detectable infec-
tion within 1 week despite a relatively high viral load of
4  108 GEq/ml (up to 800 GEq/cell).
Expanding the assay duration, we detected delayed infection
for the initially negative sera #4, #5, #7 with 2, 16 and 5% HBV-
positive cells at 8 wpi (Table 1). We monitored secreted viral
structural antigens, and viral genomes over 8 weeks via ELISA
and qPCR. Due to the high input virus inoculum, HBV genomes
and HBsAg decreased during the ﬁrst weeks, before viral mark-
ers increased at later assay time points in most cases of HBVpt
infections. The earliest time point of inﬂection of viral genomes
was determined at 1 wpi for patient #2 and at 3 wpi for patients
#3, #5, and #6. Due to the relatively lower sensitivity of ELISA,
HBsAg inﬂection was detectable 1–3 weeks later. The weekly
increasing secretion rate reached between 6  103–
5  108 GEq/ml and <0.1 to up to 316 ng/ml HBsAg at 7 or
8 wpi, paralleled by the expansion of HBV-infected cells by viral
spread. Differences in the secretion capacity correlated clearly
with the range of infection rates between 3–78%. For HBVcc
genotype D and B, the time point of inﬂection was reached at
1 and 3 wpi, respectively. Taken together, the larger inocula of296 Journal of Hepatology 2of SHBs were secreted weekly during the last 3 weeks, respec-
tively, indicating a 200- and 10-fold higher ratio of secreted
genomes per SHBs for genotype D HBVcc.
To evaluate the HBV patient strain-speciﬁc antiviral treat-
ment sensitivity, HepG2-NTPCsec+ were inoculated with 0.6 ll
(400 GEq/cell, 3  107 GEq/ml) serum of patient #1, the 2-fold
minimal infectious dose (Fig. 7A), resulting in a low initial infec-
tion rate. Until 3 wpi, only minor secretion of HBVpt genomes
and clearance of input HBsAg were observed (Fig. 7B). At
4 wpi, HBVpt genome and HBsAg secretion increased signiﬁ-
cantly with a 50-fold net ampliﬁcation of accumulated secreted
viral genomes until 8 wpi relative to input (1.6  109 GEq/ml).
HBcAg staining revealed that ampliﬁcation of secreted viral
markers was paralleled by de novo infection of naïve cells
increasing from 9% up to 70% within 8 weeks (Fig. 7C). Anti-
HBs antibody, anti-preS1 antibody MA18/7 (data not shown),
and MyrB blocked both ampliﬁcation of secreted viral markers
and de novo infection by HBV progeny (Fig. 7B-C). Inhibition
by LMV underscored that newly produced viral progeny caused
the increase in de novo infected cells. During the ramp-up phase
of the viral spread between 3–7 wpi, secreted HBV genomes
ampliﬁed with a markedly shorter t2 (5.9 days) relative to t2
in de novo infected cells (14.2 days). Consequently, the number019 vol. 71 j 289–300
of secreted HBV genomes per infected cell per day increased
nearly 5-fold between 3 and 8 wpi (Fig. 7D).
for efﬁcient ampliﬁcation of infectious patient- or cell culture-
derived HBV (reviewed in 12). Cell culture systems for in vitro
Table 1. Genotype-specific amplification and spread kinetics of patient- and cell culture-derived HBV in HepG2-NTCPsec+. HepG2-NTCPsec+ were
inoculated with 5 ll serum of 7 different patients with genotype C CHB, bearing different viral loads or with cell culture-derived genotype D or B HBV and
cultured for 8 weeks. The ratio of infected cells and secreted viral markers were monitored. Data presented as means of 1 experiment. Supernatants of 12
wells/data-point (384-well plate) were pooled and analyzed in duplicates.
Source Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Cell culture
Genotype C1 C C C C1 C C D B
Inoculum GEq/ml 5.45E+08 1.45E+08 4.07E+07 1.05E+06 1.83E+05 2.14E+06 3.46E+07 1.00E+07 1.49E+08
HBs ng/ml 1.30E+04 2.30E+04 1.53E+03 3.27E+02 3.94E+02 5.02E+02 4.13E+03 0.81 8.93
Ratio GEq/HBs 4.19E+04 6.30E+03 2.66E+04 3.21E+03 4.64E+02 4.26E+03 8.38E+03 1.23E+07 8.39E+04
Weeks post
infection
1 % infected cells 33 12 5 0.2 0.3 3 0.4 9 9
GEq/ml 2.10E+07 * 3.30E+07 2.10E+06 3.30E+05 7.00E+03 6.00E+05 7.90E+06 6.00E+07 * 7.30E+07
HBs ng/ml 6.50E+02 6.32E+02 5.3E+02 1.86E+02 6.20E+01 6.42E+02 1.91E+02 4.00 9.00
Ratio GEq/HBs 3.23E+04 5.22E+04 3.96E+03 1.77E+03 1.13E+02 9.35E+02 4.14E+04 1.50E+07 8.11E+06
2 % infected cells 62 45 14 0.7 0.9 12 2 10 27
GEq/ml 4.00E+07 2.00E+07 1.10E+05 1.60E+05 4.30E+03 3.90E+05 3.40E+05 1.00E+08 2.40E+07
HBs ng/ml 3.03E+02 4.84E+02 1.22E+02 5.1E+01 1.80E+01 1.60E+02 2.20E+01 4.00 1.00E+01
Ratio GEq/HBs 1.32E+05 4.13E+04 9.02E+02 3.14E+03 2.39E+02 2.44E+03 1.55E+04 2.50E+07 2.40E+06
3 % infected cells 74 52 19 1.5 4 15 3 12 30
GEq/ml 4.90E+07 8.00E+06 4.30E+04 * 1.70E+04 1.90E+03 * 2.30E+05 * 1.70E+04 2.00E+08 1.60E+07
HBs ng/ml 1.63E+02 3.19E+02 2.3E+01 7.00 3.00 2.80E+01 1.00 4.00 8.00 *
Ratio GEq/HBs 3.01E+05 2.51E+04 1.87E+03 2.43E+03 6.33E+02 8.21E+03 1.70E+04 5.00E+07 2.00E+06
4 % infected cells 73 60 19 0.8 2 15 2 18 32
GEq/ml 6.90E+07 5.00E+06 * 4.40E+04 2.90E+03 4.80E+03 3.80E+05 2.60E+03 * 5.00E+08 1.00E+07 *
HBs ng/ml 1.43E+02 * 8.00E+01 * 6.00 2.00 1.00 1.10E+01 * <0.10 4.00 * 9.00
Ratio GEq/HBs 4.83E+05 6.25E+04 7.33E+03 1.45E+03 4.80E+03 3.45E+04 >2.60E+04 1.25E+08 1.11E+06
5 % infected cells 75 60 22 0.9 6 26 3 32 46
GEq/ml 1.90E+08 1.20E+07 1.30E+05 1.40E+03 * 2.00E+04 1.20E+06 2.90E+03 1.00E+09 7.80E+07
HBs ng/ml 2.50E+02 1.13E+02 2.00 * 1.00 1.00 * 2.80E+01 <0.10 1.20E+01 2.50E+01
Ratio GEq/HBs 7.60E+05 1.06E+05 6.50E+04 1.40E+03 2.00E+04 4.29E+04 >2.90E+04 8.33E+07 3.12E+06
6 % infected cells 68 67 31 5.3 12 41 7 51 51
GEq/ml 4.30E+08 3.80E+07 4.60E+05 3.90E+03 9.60E+04 6.60E+06 3.80E+03 2.00E+09 2.00E+08
HBs ng/ml 2.72E+02 1.38E+02 1.10E+01 <0.10 2.00 6.00E+01 <0.10 2.90E+01 3.10E+01
Ratio GEq/HBs 1.58E+06 2.75E+05 4.18E+04 >3.90E+04 4.80E+04 1.10E+05 >3.80E+04 6.90E+07 6.45E+06
7 % infected cells 78 72 42 2.6 7 50 3 67 65
GEq/ml 4.50E+08 4.60E+07 1.40E+06 1.30E+04 5.70E+05 1.90E+07 5.50E+03 3.00E+09 3.50E+08
HBs ng/ml 3.16E+02 1.58E+02 1.60E+01 <0.10 3.00 9.30E+01 <0.10 4.60E+01 4.50E+01
Ratio GEq/HBs 1.42E+06 2.91E+05 8.75E+04 >1.30E+05 1.90E+05 2.04E+05 >5.50E+04 6.52E+07 7.78E+06
8 % infected cells 75 71 47 2 16 59 5 67 69
GEq/ml 5.30E+08 8.90E+07 2.60E+06 8.90E+03 1.90E+05 4.40E+07 6.20E+03 7.00E+09 4.30E+08
HBs ng/ml 3.09E+02 1.68E+02 2.50E+01 <0.10 4.00 1.96E+02 <0.10 1.04E+02 4.90E+01
Ratio GEq/HBs 1.72E+06 5.30E+05 1.04E+05 >8.9E+04 4.75E+04 2.24E+05 >6.20E+04 6.73E+07 8.78E+06
CHB, chronic HBV infection; GEq, genome equivalents; HBs, HBV surface protein; HBV, hepatitis B virus.
* Time point of inﬂection.
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OF HEPATOLOGYSide-by-side, we infected with genotype D HBVcc using 60
GEq/cell (0.01 ll, 1  107 GEq/ml) for inoculation (Fig. S8). At
1 wpi, HBVcc genome and HBsAg secretion increased signiﬁ-
cantly with a 1,300-fold net ampliﬁcation of accumulated viral
genomes relative to input until 8 wpi (1.3  1010 GEq/ml)
(Fig. S8A). Calculated t2, as well as the antiviral effect via inhibi-
tor treatment were comparable between the 2 different virus
sources and genotypes. Furthermore, a partial viral rebound
after MyrB and LMV discontinuation during the last 4 weeks
were observed for both viruses. However, a partial rebound
after anti-HBs withdrawal was only detectable in genotype D
HBVcc-infected cells (Fig. S8A-C).
Discussion
Many viruses can be directly isolated from patients for propaga-
tion and passaging in cell culture and ampliﬁcation of viral pro-
geny. Such in vitro approaches allow for the selective isolation of
infectious strains within the viral quasispecies pool and the
analysis of strain-speciﬁc features, like replication efﬁciency
and treatment sensitivity. Up to date, humanized mice are usedJournal of Hepatology 2HBV infection do not support the efﬁcient secretion and ampli-
ﬁcation of progeny virus. PHHs are capable of secreting HBV
efﬁciently with published values of up to 150 IU/ml SHBs and
2  107 GEq/ml (Table S1), but are too fragile in handling, lim-
ited in susceptibility and expensive. For HepaRG as well as
HepG2-NTCP cells, lower values of 16 and 14 IU/ml SHBs and
1  106 GEq/ml are reported. The maximum weekly secretion
capacity of HepG2-NTCPsec+ reaches 253 IU/ml SHBs and up to
1  1010 GEq/ml, 2–20-fold and 500–10,000-fold more SHBs
and HBV genomes compared to published values of PHH,
HepaRG and other HepG2-NTCP cells infected with HBVcc geno-
type D.
To our knowledge, we developed the ﬁrst continuous cell
line capable of 1-step net ampliﬁcation of infectious HBV. Decel-
erated cell proliferation, extended lifespan, increased G1/S cell
ratio, balanced expression of NTCP and HSPG, high expression
of HBV-related transcription factors and low expression of
HBV restrictive factor DDX3 contribute to increased production
of infectious HBV progeny in HepG2-NTCPsec+. Our results con-
ﬁrm previous reports showing that cellular factors restricting
HBV replication are linked to the differentiation status of hepa-019 vol. 71 j 289–300 297
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Research Article Viral Hepatitistocytes during an extended G1 phase and a prolonged cell
cycle.16 In HBV-transfected HepG2 cells, the formation of
cccDNA and release of infectious viral progeny can be upregu-
lated by G1 arrest.17
Furthermore, our results indicated that HBsAg envelopment
and infectious HBV particle egress are cell-type-dependent.
Supernatants of HBV-transfected HepAD38 cells harbored pre-
dominantly defective naked capsids, which were reported to
exit stable HBV-transfected cells via an alternative secretion
pathway compared to virions.18 In contrast, infected HepG2-
NTCPsec+ released high levels of LHBs-enveloped virions but
no detectable naked capsids. An excess of secreted naked cap-
sids is likely an aberrant product of transfected hepatoma cells
where HBV replication is driven by chromosomally integrated
HBV DNA, exhibiting epigenetic regulation distinct from that
of viral replication driven by episomal cccDNA in infected cells.
Naked capsids were also absent in the serum of patient #1.
However, high levels of RNA-containing naked capsids were
reported to be present in the blood of reverse transcription-
inhibitor treated patients.19 Whether the presence of naked cap-
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remains controversial, as a recent study reported an association
between circulating HBV RNA and serum alanine aminotrans-
ferase level.20
Considering the overall hepatocyte abundance in the liver
and the low virus doses subjected to most common host-to-
host transmission (i.e. sexual or percutaneous), infection begins
with only a few infected cells and undetectably low viremia
before the virus spreads through the liver within weeks or
months, resulting in the establishment of acute HBV infection.21
Restricted lifespans of cell cultures, generally not exceeding 3–
4 weeks, have hampered in vitro investigations of late-phase
kinetics of acute HBV infections. To mimic HBV ampliﬁcation
during acute infection establishment in the host, at least par-
tially, we devised conditions for long-term infection experi-
ments, including culturing of HepG2NTCPsec+ in 384-well
plates with 2.5% DMSO and weekly medium exchanges. The 2
phases of viral ampliﬁcation kinetics observed here may corre-
late with the so-called diagnostic window in patients with HBV:
the virus is initially undetectable in the blood and increases
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OF HEPATOLOGYWith a mean t2 of 5.9 and 6.5 days for genotype C HBVpt and
genotype D HBVcc, respectively, HepG2-NTCPsec+ ampliﬁed
both viruses with nearly identical kinetics during the ramp-up
phase (3–7 wpi). In contrast, the ramp-up phase in acutely
infected patients exhibits an estimated t2 of 2.2 to 5.8 days.
22Inoculation of humanized uPA/SCID mice with higher viral loads
accelerates the onset of the ramp-up phase to 1–2 wpi.23 Here,
the effect of viral dose on infection kinetics was conﬁrmed, with
high-titer inocula similarly promoting earlier onset of the virae-
mic ramp-up phase (1–2 wpi) in HepG2-NTCPsec+.
For 3 virus preparations, HBsAg and HBV DNA titer positively
correlated in the supernatant of infected cells. However, relative
to HepG2-NTCPsec+ infected with genotype B and D HBVcc,
those infected with genotype C HBVpt produced more SHBs
and LHBs-enveloped subviral particles per capsid (Fig. S9), but
less HBV genomes, suggesting genotype-speciﬁc secretion pat-
terns. In fact, the cells secrete 200- and 10-fold more genomes
per SHBs when infected with genotype D HBVcc. Under the con-
ditions tested, we observed max. 1,300- and 36,000-fold HBV
genome and HBsAg ampliﬁcation of genotype D HBVcc, respec-
tively. With max. 50-fold, the genotype C HBVpt genome net
ampliﬁcation is signiﬁcantly reduced which is due to the low
infectivity of unpuriﬁed, crude patient serum as shown by the
high minimum infectious dose of 2  107 GEq/ml needed for
infection. Several factors may explain why our system is not
as susceptible as shown for the chimpanzee model infected with
inocula from patients in the pre-acute phase of infection.24
Here, sera were collected from patients with CHB who are
known to have a large proportion of non-infectious virus parti-
cles, e.g. antibody-neutralized virions, or preS1-rich ﬁlamentous
subviral particles potentially competing with virions for the
low-abundance preS1 receptor. Even the ampliﬁcation potential
for HBsAg cannot be calculated due to very high concentrations
of subviral particles present in the serum of patients with CHB.
However, the infection efﬁcacy and net ampliﬁcation may be
further increased by purifying HBV, as preS1-containing subvi-
ral particles and virion-antibody complexes can be partially
removed.Mechanisms of HBV progeny ampliﬁcation during the estab-
lishment of acute infection have remained poorly understood
due to the lack of suitable cell culture models. However, we
showed that the viraemic ramp-up phase was paralleled by de
novo infection of naïve cells, indicating that viral spread con-
tributed to ampliﬁcation of HBV progeny. Spread was blocked
by well described HBV entry inhibitors, reﬂecting interactions
between viral surface proteins and cell membrane receptors
(HSPGs and NTCP) as a restrictive step in HBV spread. Thus,
spreading virions seem to utilize an identical entry mechanism
to exogenously added virions during inoculation. However,
more studies on HepG2-NTCPsec+ are needed to identify further
cellular factors driving HBV spread.
In all HBV-susceptible cell culture models, efﬁcient infection
is strictly dependent on PEG during inoculation. PEG is required
for the interaction of viral surface proteins with HSPG for HBV
entry.11 Recent reports have demonstrated that 15% spread
was achievable in a HepG2-NTCP cell line only under continu-
ous PEG treatment.25 However, HBV spread in HepG2-NTCPsec
+ from <10–80% infection rates in the absence of PEG, with
PEG supplementation not affecting spread (Fig. S10B), indicating
that progeny virions released by HepG2-NTCPsec+ can interact
with HSPG for viral entry independently of PEG. We were
Journal of Hepatology 2unable to detect PEG-dependent- or independent spread in
HepG2-NTCPsec (Fig. S10C).
The high concentration of infectious HBV progeny in the
supernatants would suggest spread via diffusion through an
aqueous environment and random infection of single cells.
However, spread was visualized as an expansion of HBV-
infected cell clusters caused by a short-distance route of HBV
spread to neighboring cells. Our model suggested that extracel-
lular progeny virions released from de novo infected cells
favored attachment to adjacent cells which required interaction
with HSPG and NTCP at the plasma membrane for infection. In
the chimeric uPA/SCID mouse HBV-infected clusters were not
observed at 8 wpi, however, advanced microscopic studies on
the spatial–temporal distribution of HBV-infected cells in the
liver during acute infection establishment have not been
conducted.23
During the viraemic ramp-up phase, intracellular cccDNA
molecules and secreted virion rcDNA per infected cell increased
simultaneously by 8- and 10-fold, respectively, corroborating
that the cccDNA pool size is a critical factor for HBV ampliﬁca-
tion. Entry inhibitors prevented not only expansion of HBcAg-
positive hepatocytes, but also the enhancement of the intrahep-
atic cccDNA pool and secreted progeny HBV, suggesting that
cccDNA ampliﬁcation is predominantly (88%) dependent on an
extracellular route of receptor-mediated infection. This is in
agreement with reports showing that MyrB blocks intrahepatic
viral spread and cccDNA accumulation in humanized mice, with
the authors concluding that intracellular recycling of nucleocap-
sids is only a minor route for cccDNA pool replenishment.26 We
estimated that, in HepG2-NTCPsec+, intracellular recycling of de
novo synthesized nucleocapsids accounts for ≤12% of the
cccDNA pool ampliﬁcation.
Our cell culture platform combines 4 clinically relevant fea-
tures of HBV-infected patients and animal models. First, HBV is
efﬁciently ampliﬁed following de novo infection. Second, all
released capsids are enveloped with LHBs and are highly infec-
tious. Third, the observed kinetics of HBV ampliﬁcation during
the establishment of acute infection resemble the multiphasic
kinetics observed in patients and infected chimeric uPA/SCID
mice.21–23 Fourth, like in infected chimpanzees, HBV does not
induce any signiﬁcant gene expression changes, underlining
the reputation of HBV as a stealth virus.15
A hallmark of our HBV platform is the exceptionally efﬁcient
ampliﬁcation and secretion of infectious viral progeny driven
by episomal cccDNA which originates from de novo HBV entry.
Compared to transfected hepatoma cells, HepG2-NTCPsec+
enable more physiological investigations of cccDNA epigenetic
regulation and production of authentically enveloped, infec-
tious HBV particles in concentrations suitable for analysis by
electron microscopy. The platform can be further used for com-
parative characterizations of HBV variants, for the ampliﬁcation
of clinical isolates using minute amounts of crude HBV patient
sera, and for the evaluation of HBV patient strain-speciﬁc fea-
tures like infectivity, viability, replication efﬁciency and antivi-
ral treatment sensitivity including neutralizing anti-HBV
antibodies, viral rebound kinetics following inhibitor with-
drawal and the evolution of drug-resistant mutant virus quasis-
pecies under antiviral treatment pressure. Thus, this platform
can elucidate the molecular biology underlying HBV morpho-
genesis, including envelopment, egress, secretion pathways
and spread.
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